[Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].
Seissler
J
J
Medizinische Klinik--Innenstadt, Klinikum der LMU München. jochen.seissler@med.uni-muenchen.de
D000218:Adamantane / Q000031:analogs & derivatives / Q000627:therapeutic use; D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D000077270:Exenatide; D006801:Humans; D050417:Insulin-Secreting Cells / Q000166:cytology / Q000187:drug effects; D007515:Islets of Langerhans / Q000166:cytology; D016381:Islets of Langerhans Transplantation; D051379:Mice; D009570:Nitriles / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D012038:Regeneration / Q000187:drug effects / Q000502:physiology; D000068900:Sitagliptin Phosphate; D033581:Stem Cell Transplantation; D014183:Transplantation, Heterologous; D014230:Triazoles / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use; D000077597:Vildagliptin
D009570:Nitriles; D010455:Peptides; D011719:Pyrazines; D011759:Pyrrolidines; D014230:Triazoles; D014688:Venoms; D000077270:Exenatide; D000077597:Vildagliptin; D000218:Adamantane; D000068900:Sitagliptin Phosphate